Back to top
more

Pfizer (PFE)

(Real Time Quote from BATS)

$29.20 USD

29.20
12,922,186

+0.23 (0.79%)

Updated Sep 27, 2024 01:16 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

BioMarin (BMRN) Q2 Earnings Miss Estimates, Revenues Beat

by Zacks Equity Research

BioMarin (BMRN) reports mixed second-quarter results with earnings missing estimates but sales beating the same.

    Is Pfizer (PFE) a Good Pick for Income Investors?

    by Zacks Equity Research

    Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Pfizer (PFE) have what it takes? Let's find out.

      PFE vs. MRK: Which Stock Should Value Investors Buy Now?

      by Zacks Equity Research

      PFE vs. MRK: Which Stock Is the Better Value Option?

        Swarup Gupta headshot

        Dow 30 Stock Roundup: Apple, DowDuPont, Caterpillar, Pfizer Earnings Impress

        by Swarup Gupta

        The index endured a difficult week, marked by a decline in tech stocks and trade war fears.

          Drug Stock Q2 Earnings Releases on Aug 2: ZTS, REGN & More

          by Zacks Equity Research

          Let's see how these pharma/biotech stocks are poised ahead of their scheduled results on Aug 2.

            Stock Market News For Aug 1, 2018

            by Zacks Equity Research

            Markets rebounded on Tuesday on reports that the United States and China are willing to start talks in an effort to resolve trade disputes.

              Economic Data Deluge

              by Zacks Equity Research

              Economic Data Deluge

                Mark Vickery headshot

                Costs, Spending Data Join New Q2 Earnings for PFE, PG, RL

                by Mark Vickery

                Employee Cost Index, PCE and Consumer Spending all hit the tape this morning, along with another helping of Q2 earnings reports.

                  Pfizer (PFE) Beats on Q2 Earnings & Sales, Ups Profit View

                  by Zacks Equity Research

                  Pfizer (PFE) beats expectations for earnings as well as sales in the second quarter. It raises earnings expectations for 2018 but slightly lowers the sales range.

                    Pfizer (PFE) Surpasses Q2 Earnings and Revenue Estimates

                    by Zacks Equity Research

                    Pfizer (PFE) delivered earnings and revenue surprises of 8.00% and 1.58%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

                      Aerie (AERI) to Report Q2 Earnings: What's in the Offing?

                      by Zacks Equity Research

                      Investors will focus on Rhopressa's initial uptake, and other pipeline and regulatory updates, when Aerie (AERI) reports Q2 results.

                        Afrasiab Mian headshot

                        Pfizer (PFE) Ticks Up Ahead of Earnings: What To Expect

                        by Afrasiab Mian

                        Shares of Pfizer Inc. (PFE) ticked up 0.5% during regular hours Monday, the last day of trading before the pharmaceutical giant releases its latest quarterly earnings report. Here's what to expect on Tuesday morning.

                          BioMarin (BMRN) to Report Q2 Earnings: What's in the Cards?

                          by Zacks Equity Research

                          BioMarin (BMRN) is likely to see continued momentum in Kuvan and Vimizim sales in the second quarter. On the call, management is likely to comment on the launch preparation for pegvaliase.

                            Drug Stocks to Report Q2 Earnings on Jul 31: PFE, INCY, ECYT

                            by Zacks Equity Research

                            Let's see how pharma/biotech stocks are poised ahead of their scheduled results on Jul 31.

                              Pharma Stock Roundup: LLY, AGN Post Solid Q2 Results, ABBV's Elagolix Gets FDA Nod

                              by Zacks Equity Research

                              Earnings are in focus this week with Lilly (LLY), Allergan (AGN) and Glaxo (GSK) delivering strong Q2 numbers. AbbVie (ABBV) gains FDA approval for Elagolix.

                                Amgen (AMGN) Q2 Earnings & Sales Beat Estimates, View Up

                                by Zacks Equity Research

                                Amgen (AMGN) impresses with better-than-estimated second-quarter results and raises its outlook for the full year. Shares rise in after-hours trading.

                                  Bristol-Myers (BMY) Beats on Q2 Earnings, Raises Outlook

                                  by Zacks Equity Research

                                  Bristol-Myers (BMY) beats estimates on both counts in the second quarter. Eliquis and Opdivo continue to record solid sales.

                                    Merck's Keytruda Improves Survival in Head/Neck Cancer Study

                                    by Zacks Equity Research

                                    Merck's (MRK) key cancer drug Keytruda succeeds as a monotherapy in phase III program. It is being evaluated for the first-line treatment of patients with advanced head and neck cancer.

                                      Will Pfizer (PFE) Keep the Earnings Streak Alive in Q2?

                                      by Zacks Equity Research

                                      While Pfizer's (PFE) new drugs like Ibrance and Xeljanz are likely to drive Q2 sales, genericization of key drugs and supply shortages in legacy Hospira products will hurt the same.

                                        Merck (MRK) Q2 Earnings Coming Up: What's in the Cards?

                                        by Zacks Equity Research

                                        Merck's (MRK) new products like Keytruda and Bridion are likely to drive second-quarter sales. However, headwinds remain in the form genericization of key drugs and increasing competition.

                                          Is a Beat in the Cards for AbbVie (ABBV) in Q2 Earnings?

                                          by Zacks Equity Research

                                          Impressive sales of AbbVie's (ABBV) key drugs, Humira, Imbruvica and Mavyret, might lead the company to an earnings beat in the second quarter.

                                            Lilly (LLY) Tops Q2 Earnings, Chooses IPO Path for Elanco

                                            by Zacks Equity Research

                                            Eli Lilly (LLY) tops estimates for both earnings and sales in the second quarter and raises guidance for 2018. It will divest its Elanco unit into a new public company. Stock up in pre-market trading.

                                              Is a Beat in Store for Keryx (KERX) This Earnings Season?

                                              by Zacks Equity Research

                                              Keryx (KERX) is likely to provide updates on the merger with Akebia along with the updates on Auryxia at the second quarter call.

                                                What's in the Cards for Glaxo (GSK) This Earnings Season?

                                                by Zacks Equity Research

                                                Glaxo's (GSK) Pharmaceuticals and Vaccines segments are likely to boost sales in Q2 earnings.

                                                  Is a Beat in Store for Alexion (ALXN) This Earnings Season?

                                                  by Zacks Equity Research

                                                  Alexion is likely to provide details about the pipeline portfolio when it reports its second-quarter 2018 results on Jul 26.